āThe following medications have been removed from the ADAP Formulary because they are no longer available from the manufacturer(s):
| saquinavir | Invirase | Antiretroviral | 8/21/2023 |
| delavirdine | Rescriptor | Antiretroviral | 8/21/2023 |
| fomivirsen | Vitravene | Antiviral | 8/21/2023 |
| interferon alfacon-1 | Infergen | Antiviral | 1/20/2023 |
| codeine w/ASA | generic | Analgesic | 8/21/2023 |
| isoniazid/rifampin | Rifamate | Antibiotics | 8/21/2023 |
| ranitidine HCL | Zantac | Hā Blockers | 8/21/2023 |
| capreomycin | Capastat | Antibiotics | 8/21/2023 |
| lamivudine/tenofovir disoproxil fumarate* | Temixys | Antiretroviral | 8/21/2023 |
| interferon alfa-2bā | Intron-A | Immunomodulators | 2/6/2023 |
| interferon alfa-2aā | Roferon-A | Antineoplastic Interferons | 2/6/2023 |
| ribavirin | Rebetol | Antiviral | 2/6/2023 |
| ribavirin/interferon alfa-2B | Rebetron | Antiviral | 2/6/2023 |
| Peginterferon alfa-2Bā | Peg-Intron | Interferons | 2/6/2023
|
* Temixys's version of lamivudine/tenofovir disoproxil fumarate has been removed, but other commercially available versions of the medication are still on the formulary.
ā Several interferon products are no longer commercially available and have been removed, but Pegasys pegylated interferon alfa-2a is still on the formulary.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the removal of these medications. Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents.
If you have any questions regarding the removal of these medications from the ADAP formulary, please contact the OA Formulary Specialist, James Vo (James.Vo@cdph.ca.gov).
Thank you,
Joseph Lagrama
ADAP Branch Chief
California Department of Public Health